360 related articles for article (PubMed ID: 35336986)
1. Therapeutic Strategies against Ebola Virus Infection.
Liu CH; Hu YT; Wong SH; Lin LT
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336986
[TBL] [Abstract][Full Text] [Related]
2. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.
Dhama K; Karthik K; Khandia R; Chakraborty S; Munjal A; Latheef SK; Kumar D; Ramakrishnan MA; Malik YS; Singh R; Malik SVS; Singh RK; Chaicumpa W
Front Immunol; 2018; 9():1803. PubMed ID: 30147687
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.
Soni M; Tulsian K; Barot P; Vyas VK
Recent Adv Antiinfect Drug Discov; 2024; 19(4):276-299. PubMed ID: 38279760
[TBL] [Abstract][Full Text] [Related]
4. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
5. The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.
Wu W; Liu S
Curr Top Med Chem; 2017; 17(3):361-370. PubMed ID: 27572081
[TBL] [Abstract][Full Text] [Related]
6. Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.
Kasereka MC; Mumtaz Z; Hawkes MT
Drugs Today (Barc); 2021 Jan; 57(1):27-45. PubMed ID: 33594388
[TBL] [Abstract][Full Text] [Related]
7. Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.
Wang H; Wong G; Zhu W; He S; Zhao Y; Yan F; Rahim MN; Bi Y; Zhang Z; Cheng K; Jin H; Cao Z; Zheng X; Gai W; Bai J; Chen W; Zou Y; Gao Y; Gao GF; Yang S; Xia X; Qiu X
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541860
[TBL] [Abstract][Full Text] [Related]
8. Ebola-Detect: A differential serodiagnostic assay for Ebola virus infections and surveillance in the presence of vaccine-induced antibodies.
Ravichandran S; Khurana S
EBioMedicine; 2022 Aug; 82():104186. PubMed ID: 35901660
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
mBio; 2019 May; 10(3):. PubMed ID: 31138743
[TBL] [Abstract][Full Text] [Related]
10. [Overview of Ebola virus vaccine].
Yang L; Li J; Gao GF; Liu W
Sheng Wu Gong Cheng Xue Bao; 2015 Jan; 31(1):1-23. PubMed ID: 26021076
[TBL] [Abstract][Full Text] [Related]
11. Recent developments and strategies of Ebola virus vaccines.
Sharma AR; Lee YH; Nath S; Lee SS
Curr Opin Pharmacol; 2021 Oct; 60():46-53. PubMed ID: 34329960
[TBL] [Abstract][Full Text] [Related]
12. Ebola virus outbreak preparedness plan for developing Nations: Lessons learnt from affected countries.
Gupta S; Gupta N; Yadav P; Patil D
J Infect Public Health; 2021 Mar; 14(3):293-305. PubMed ID: 33610938
[TBL] [Abstract][Full Text] [Related]
13. Ebola Virus: Pathogenesis and Countermeasure Development.
Furuyama W; Marzi A
Annu Rev Virol; 2019 Sep; 6(1):435-458. PubMed ID: 31567063
[TBL] [Abstract][Full Text] [Related]
14. Toward an Effective Ebola Virus Vaccine.
Keshwara R; Johnson RF; Schnell MJ
Annu Rev Med; 2017 Jan; 68():371-386. PubMed ID: 27686015
[TBL] [Abstract][Full Text] [Related]
15. Against the clock towards new Ebola virus therapies.
Martínez-Romero C; García-Sastre A
Virus Res; 2015 Nov; 209():4-10. PubMed ID: 26057711
[TBL] [Abstract][Full Text] [Related]
16. A review on the antagonist Ebola: A prophylactic approach.
Khan FN; Qazi S; Tanveer K; Raza K
Biomed Pharmacother; 2017 Dec; 96():1513-1526. PubMed ID: 29208326
[TBL] [Abstract][Full Text] [Related]
17. Development of therapeutics for treatment of Ebola virus infection.
Li H; Ying T; Yu F; Lu L; Jiang S
Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
[TBL] [Abstract][Full Text] [Related]
18. The Methanolic Extract of
Kuo YT; Liu CH; Corona A; Fanunza E; Tramontano E; Lin LT
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578374
[TBL] [Abstract][Full Text] [Related]
19. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
[TBL] [Abstract][Full Text] [Related]
20. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
Tshiani Mbaya O; Mukumbayi P; Mulangu S
Front Immunol; 2021; 12():721328. PubMed ID: 34526994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
